Global Expansion Strategy

Apex AI has a three-stage international expansion plan focusing on Korea, the U.S., and Japan, followed by a broader global rollout.

2025-26: Domestic Market Expansion (South Korea)

• Clinical validation with major hospitals, including:

  • Seoul National University Bundang Hospital

  • Inha University Hospital

  • Hanlim University Sacred Heart Hospital

• Initial rollout in health screening centers with direct sales and platform partnerships.

• AI-powered digestive health monitoring collaboration with Next Biomed & iKooB.

2025-26: Entry into the U.S. Market

• Pilot program in Utah (Phase 2 region) before expanding to key medical hubs like New York, California, Boston, and Texas.

• Strategic collaborations with top-tier U.S. institutions, including:

  • Harvard Medical School (MGH) – Two professors onboarding as advisors.

  • Oracle Healthcare – AI integration partnerships.

  • Medtronic – Exploring collaboration on medical AI devices.

• Investment network expansion – Attracting U.S.-based investors to establish a sustainable market presence.

Japan Expansion

• AI licensing to endoscopy manufacturers, including Olympus, Pentax, and Fujifilm.

• Partnership with CEC (Fujitsu subsidiary) to penetrate Japanese medical institutions.

• Regulatory alignment for market approval and expansion into hospitals & screening centers.

Post-2027: Global Expansion

• Following successful market entries in Korea, the U.S., and Japan, Apex AI will scale into Europe, China, and other high-demand regions.

• Cloud-based AI diagnostics will drive accessibility, making Apex AI a global leader in AI-powered gastrointestinal cancer detection.